Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 R&D news flow with several regulatory decisions in the past six months Slide 15 Results available Regulatory milestone Project Past 6-9 months Past 3-6 months Within months In 3-6 months TresibaⓇ SWITCH 1 Variation application in the USA DEVOTE Variation application in EU Once-weekly semaglutide SUSTAIN 5 EASD - Detailed results from SUSTAIN 6 ✓ USA and EU submission SUSTAIN 6 Variation applications VictozaⓇ LEADER XultophyⓇ Faster-acting N9-GP Concizumab Somapacitan Phase 3a¹ in the USA and EU FDA AdComm ✓ FDA regulatory decision FDA regulatory decision CHMP opinion EMA regulatory decision USA submission CHMP opinion Diabetes Haemophilia Growth disorders Note: Indicated timeline as of financial release of first nine months of 2016 on 28 October 2016; 1 Study conducted in adult growth hormone disorder CRL: Complete Response Letter changing diabetes® Phase 1 results novo nordisk

View entire presentation